AXL 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for AXL is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
151 Direct drug records from Target & Disease MCP | 119 Development records in target context | 396 Disease associations captured | 707 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
AXL connects GAS6 signaling, survival, migration, and immune suppression
Target & Disease MCP profiles AXL as a GAS6-binding receptor tyrosine kinase that activates PI3K-AKT, GRB2, PLCG1, LCK, PTPN11, and related signaling. It regulates survival, proliferation, migration, differentiation, thrombotic responses, NK-cell development, hepatic regeneration, and inhibition of TLR-mediated innate immunity.
Validation supports oncology and immune-resistance positioning
The MCP workflow retrieved 151 direct drug records, 119 development records, and 396 disease associations. Clinical Trials MCP returned 707 trial records, consistent with AXL as a resistance, EMT, immune microenvironment, and multikinase-development target.
Clinical competition often appears through multikinase agents
Recent trials include zanzalintinib plus pembrolizumab, zanzalintinib in adenoid cystic carcinoma, and NIMBLE-CRC. These point to an immuno-oncology and multikinase competitive context rather than purely AXL-selective development.
IP and strategy view
AXL IP should focus on immune-resistance biomarkers, TAM-family selectivity, combinations with checkpoint blockade, and tumor states where AXL biology is causal.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 707 registered trial records connected to AXL. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| Zanzalintinib plus pembrolizumab in resectable clear-cell renal-cell carcinoma | Phase 2 | Not yet recruiting |
| Zanzalintinib in relapsed or metastatic adenoid cystic carcinoma | Phase 2 | Not yet recruiting |
| NIMBLE-CRC: neo-immunomodulation before excision in colorectal/rectal cancer | Phase 2 | Not yet recruiting |
R&D Strategy Recommendation
AXL is attractive when framed as a resistance and immune-modulation target. A strong program needs biomarker-driven enrollment and a clear combination rationale.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
